Shankarkumar U, Sridharan B
Human Leukocyte Antigen and Transplantation Department, Department of Medicine National Institute of Immunohaematology, KEM Hospital, Parel, Mumbai, India.
J Nat Sci Biol Med. 2011 Jul;2(2):205-8. doi: 10.4103/0976-9668.92323.
The central nervous system tumors are a rare neoplasm with little knowledge with Human Leukocyte Antigen (HLA) involvement. Primary brain tumors are cancers that originate in brain classified according to their appearance under a microscope as low grade (grade I and II) with diffuse astrocytomas, pliocytic astrocytomas, oligodendrogliomas, gangliogliomas, and mixed gliomas as common subtypes and high grade (grade III and IV).
HLA associations in common glioma are reported from other parts of the world. The normal cancer treatment is surgery, followed by radiotherapy, and chemotherapy; nowadays immunotherapy is advised. HLA distribution in a Glioma patient was done based on serology and molecular techniques. The immune response gene studies have implicated the HLA allele association in most of the common diseases from India. Considerable variations are noted in HLA association with cancers; hence, we have summarized the HLA involvement in Glioma with respect to the literature.
HLA A030101, A310102, B350101, B4406, Cw040101, Cw070101, DRB1070101, and DRB11001.
Ethnic diversity and HLA polymorphism precipitate differential immune response genes involved in variable disease manifestations. Therefore, caste-specific HLA allelic specificity needs to be identified, which may help in early identification of the associated HLA allele and establishing clinical practices among glioma patients.
中枢神经系统肿瘤是一种罕见的肿瘤，人们对其与人类白细胞抗原（HLA）的关系了解甚少。原发性脑肿瘤是起源于大脑的癌症，根据显微镜下的外观可分为低级别（I级和II级），常见亚型包括弥漫性星形细胞瘤、毛细胞型星形细胞瘤、少突胶质细胞瘤、神经节胶质瘤和混合性胶质瘤，以及高级别（III级和IV级）。
世界其他地区报道了常见胶质瘤中的HLA关联。常规癌症治疗方法是手术，随后进行放疗和化疗；如今建议采用免疫疗法。基于血清学和分子技术对一名胶质瘤患者的HLA分布进行了研究。免疫反应基因研究表明，HLA等位基因关联与印度的大多数常见疾病有关。HLA与癌症的关联存在相当大的差异；因此，我们根据文献总结了HLA在胶质瘤中的作用。
HLA A030101、A310102、B350101、B4406、Cw040101、Cw070101、DRB1070101和DRB11001。
种族多样性和HLA多态性导致参与不同疾病表现的免疫反应基因存在差异。因此，需要确定特定种姓的HLA等位基因特异性，这可能有助于早期识别相关的HLA等位基因，并在胶质瘤患者中建立临床实践。
